Trials / Completed
CompletedNCT03689114
Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)
Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Mario Negri Institute for Pharmacological Research · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
There are no guidelines on the first maintenance daily dose of antiepileptic drugs (AEDs) in newly diagnosed, previously untreated epilepsy. Original trials and Cochrane reviews show that seizure remission can be achieved with differing daily doses. In clinical practice, the first maintenance dose varies significantly. In contrast, the risk of adverse treatment effects increases with dosage. There is thus the need to identify the lowest effective dose for treatment start. This background prompted us to undertake a randomized multicenter pragmatic non-inferiority trial comparing standard to low daily doses of AEDs to demonstrate that low doses are at least as effective as standard doses (as indicated by the national formulary) but are better tolerated and are associated with a better quality of life. If proven as effective as the standard dose, a low daily dose of AEDs is a benefit to the patient in terms of tolerability and safety and a source of savings for the National Health System.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Low dose carbamazepine | Carbamazepine, 300 mg/die |
| DRUG | Standard dose carbamazepine | Carbamazepine 600 mg/die |
| DRUG | Low dose levetiracetam | Levetiracetam 500 mg/die |
| DRUG | Standard dose levetiracetam | Levetiracetam 1000 mg/die |
| DRUG | Low dose valproate | Valproate 300 mg/die |
| DRUG | Standard dose valproate | Valproate 600 mg/die |
| DRUG | Low dose zonisamide | Zonisamide 150 mg/die |
| DRUG | Standard dose zonisamide | Zonisamide 300 mg/die |
| DRUG | Low dose oxcarbazepine | Oxcarbazepine 600 mg/die |
| DRUG | Standard dose oxcarbazepine | Oxcarbazepine 1200 mg/die |
| DRUG | Low dose topiramate | Topiramate 100 mg/die |
| DRUG | Standard dose topiramate | Topiramate 200 mg/die |
| DRUG | Low dose lamotrigine | Lamotrigine 100 mg/die |
| DRUG | Standard dose lamotrigine | Lamotrigine 200 mg/die |
| DRUG | Low dose gabapentin | Gabapentin 450 mg/die |
| DRUG | Standard dose gabapentin | Gabapentin 900 mg/die |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2024-06-30
- Completion
- 2024-06-30
- First posted
- 2018-09-28
- Last updated
- 2025-07-08
- Results posted
- 2025-07-08
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03689114. Inclusion in this directory is not an endorsement.